PHASE I STUDIES

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

Raymond, Éric E.
Faivre, Sandrine
Alexandre, Jérôme
Goldwasser, François
Besse-Hammer, Tatiana
Awada, Ahmad
Gianella-Borradori, Athos
Jego, V.
Trandafir, Lucia
Rejeb, Narmyn

January 2014

Introduction: MSC1992371A is an aurora kinase inhibitor with potential antitumor activity. Methods: ...

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

Punt, C. J.
van Maanen, L.
Bol, C. J.
Seifert, W. F.
Wagener, D. J.

January 2001

R115777 is a novel selective inhibitor of farnesyl transferase, an enzyme that is involved in the pr...

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling

Kolb, EA
Gorlick, R
Keir, ST
Maris, JM
Lock, RB
Carol, H
Kurmasheva, RT
Reynolds, CP
Kang, MH
Wu, J
Houghton, PJ
Smith, MA

January 2012

RO4929097 is a potent and selective inhibitor of gamma-secretase and as a result is able to inhibit ...

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter, S
Bedard, PL
Chen, EX
Clarke, BA
Tran, B
Hotte, SJ
Stathis, A
Hirte, HW
Razak, ARA
Reedijk, M
Chen, Z
Cohen, B
Zhang, W-J
Wang, L
Ivy, SP
Moore, MJ
Oza, AM
Siu, LL
McWhirter, E

April 2014

PURPOSE: To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO)...

A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Cook, N.
Basu, B.
Smith, D. M.
Gopinathan, A.
Evans, J.
Steward, W. P.
Palmer, D.
Propper, D.
Venugopal, B.
Hategan, M.
Anthoney, D. A.
Hampson, L. V.
Nebozhyn, M.
Tuveson, D.
Farmer-Hall, H.
Turner, H.
McLeod, R.
Halford, S.
Jodrell, D.

March 2018

BACKGROUND: The Notch pathway is frequently activated in cancer. Pathway inhibition by gamma-secreta...

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triplenegative breast cancer

Locatelli, Marzia Adelia
Shaik, Mahmood Naveed
Kern, Kenneth K.A.
Curigliano, Giuseppe
Aftimos, Philippe
Claire Dees, E.
LoRusso, Patricia Mucci
Pegram, Mark
Awada, Ahmad
Huang, Bo
Cesari, Rossano
Jiang, Yuqiu

January 2017

Background: The NOTCH signaling pathway may be involved in the survival of stem cell-like tumor-init...

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Koolen, Stijn L. W.
Witteveen, Petronella O.
Jansen, Robert S.
Langenberg, Marlies H. G.
Kronemeijer, Roelien H.
Nol, Annemarie
Garcia-Ribas, Ignacio
Callies, Sophie
Benhadji, Karim A.
Slapak, Christopher A.
Beijnen, Jos H.
Voest, Emile E.
Schellens, Jan H. M.

September 2011

Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to...

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, Jeffry
Steward, William P
Palmer, Daniel
Propper, David
Venugopal, Balaji
Hategan, Mirela
Anthoney, D Alan
Hampson, Lisa V
Nebozhyn, Michael
Tuveson, David
Farmer-Hall, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah
Jodrell, Duncan

March 2018

BACKGROUND: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase i...

Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Stuurman, Frederik
Voest, E.E.
Awada, Ahmad
Witteveen, Petronella
Bergeland, T.
Hals, Petter Arnt
Rasch, Wenche
Schellens, Jan J.H.M.
Hendlisz, Alain

August 2013

Summary: CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The pur...

Phase I clinical and pharmacological studies with the non-classical thymidylate synthase inhibitor AG337

Rafi, I.

January 1998

SIGLEAvailable from British Library Document Supply Centre-DSC:DXN023012 / BLDSC - British Library D...

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, T.R. Jeffry
Steward, William P.
Palmer, Dan
Propper, David
Venugopal, Balaji
Hategan, Mirela
Anthoney, D. Alan
Hampson, Lisa V.
Nebozhyn, Michael
Tuveson, Dave
Farmer-Hall, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah
Jodrell, Duncan

March 2018

Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase ...

gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells

Yao, J.
Duan, L.
Fan, M.
Wu, X.

November 2007

Objective To investigate the effect of the gamma-secretase inhibitors (GSIs) on the growth of human ...

Phase I Study of FixedDoseRate Infusion ofGemcitabine in Patients with Unresectable Pancreatic Cancer

Junji Furuse
Hiroshi Ishii
Takuji Okusaka
Michitaka Nagase
Kohei Nakachi
Hideki Ueno
Masafumi Ikeda
Chigusa Morizane
Masahiro Yoshino

January 2005

Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administ...

PHASE I STUDIES

Zev A. Wainberg

January 2013

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subject...

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.

Punt, C.J.A.
Maanen, L.W.G.M. van
Bol, C.J.
Seifert, W.F.
Wagener, D.J.T.

January 2001

R115777 is a novel selective inhibitor of farnesyl transferase, an enzyme that is involved in the pr...

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

Raymond, Éric E.
Faivre, Sandrine
Alexandre, Jérôme
Goldwasser, François
Besse-Hammer, Tatiana
Awada, Ahmad
Gianella-Borradori, Athos
Jego, V.
Trandafir, Lucia
Rejeb, Narmyn

January 2014

Introduction: MSC1992371A is an aurora kinase inhibitor with potential antitumor activity. Methods: ...

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

Punt, C. J.
van Maanen, L.
Bol, C. J.
Seifert, W. F.
Wagener, D. J.

January 2001

R115777 is a novel selective inhibitor of farnesyl transferase, an enzyme that is involved in the pr...

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling

Kolb, EA
Gorlick, R
Keir, ST
Maris, JM
Lock, RB
Carol, H
Kurmasheva, RT
Reynolds, CP
Kang, MH
Wu, J
Houghton, PJ
Smith, MA

January 2012

RO4929097 is a potent and selective inhibitor of gamma-secretase and as a result is able to inhibit ...

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter, S
Bedard, PL
Chen, EX
Clarke, BA
Tran, B
Hotte, SJ
Stathis, A
Hirte, HW
Razak, ARA
Reedijk, M
Chen, Z
Cohen, B
Zhang, W-J
Wang, L
Ivy, SP
Moore, MJ
Oza, AM
Siu, LL
McWhirter, E

April 2014

PURPOSE: To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO)...

A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Cook, N.
Basu, B.
Smith, D. M.
Gopinathan, A.
Evans, J.
Steward, W. P.
Palmer, D.
Propper, D.
Venugopal, B.
Hategan, M.
Anthoney, D. A.
Hampson, L. V.
Nebozhyn, M.
Tuveson, D.
Farmer-Hall, H.
Turner, H.
McLeod, R.
Halford, S.
Jodrell, D.

March 2018

BACKGROUND: The Notch pathway is frequently activated in cancer. Pathway inhibition by gamma-secreta...

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triplenegative breast cancer

Locatelli, Marzia Adelia
Shaik, Mahmood Naveed
Kern, Kenneth K.A.
Curigliano, Giuseppe
Aftimos, Philippe
Claire Dees, E.
LoRusso, Patricia Mucci
Pegram, Mark
Awada, Ahmad
Huang, Bo
Cesari, Rossano
Jiang, Yuqiu

January 2017

Background: The NOTCH signaling pathway may be involved in the survival of stem cell-like tumor-init...

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Koolen, Stijn L. W.
Witteveen, Petronella O.
Jansen, Robert S.
Langenberg, Marlies H. G.
Kronemeijer, Roelien H.
Nol, Annemarie
Garcia-Ribas, Ignacio
Callies, Sophie
Benhadji, Karim A.
Slapak, Christopher A.
Beijnen, Jos H.
Voest, Emile E.
Schellens, Jan H. M.

September 2011

Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to...

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, Jeffry
Steward, William P
Palmer, Daniel
Propper, David
Venugopal, Balaji
Hategan, Mirela
Anthoney, D Alan
Hampson, Lisa V
Nebozhyn, Michael
Tuveson, David
Farmer-Hall, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah
Jodrell, Duncan

March 2018

BACKGROUND: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase i...

Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Stuurman, Frederik
Voest, E.E.
Awada, Ahmad
Witteveen, Petronella
Bergeland, T.
Hals, Petter Arnt
Rasch, Wenche
Schellens, Jan J.H.M.
Hendlisz, Alain

August 2013

Summary: CP-4126 is a gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) 5′ elaidic acid ester. The pur...

Phase I clinical and pharmacological studies with the non-classical thymidylate synthase inhibitor AG337

Rafi, I.

January 1998

SIGLEAvailable from British Library Document Supply Centre-DSC:DXN023012 / BLDSC - British Library D...

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, T.R. Jeffry
Steward, William P.
Palmer, Dan
Propper, David
Venugopal, Balaji
Hategan, Mirela
Anthoney, D. Alan
Hampson, Lisa V.
Nebozhyn, Michael
Tuveson, Dave
Farmer-Hall, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah
Jodrell, Duncan

March 2018

Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase ...

gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells

Yao, J.
Duan, L.
Fan, M.
Wu, X.

November 2007

Objective To investigate the effect of the gamma-secretase inhibitors (GSIs) on the growth of human ...

Phase I Study of FixedDoseRate Infusion ofGemcitabine in Patients with Unresectable Pancreatic Cancer

Junji Furuse
Hiroshi Ishii
Takuji Okusaka
Michitaka Nagase
Kohei Nakachi
Hideki Ueno
Masafumi Ikeda
Chigusa Morizane
Masahiro Yoshino

January 2005

Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administ...

PHASE I STUDIES

Zev A. Wainberg

January 2013

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subject...

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.

Punt, C.J.A.
Maanen, L.W.G.M. van
Bol, C.J.
Seifert, W.F.
Wagener, D.J.T.

January 2001

R115777 is a novel selective inhibitor of farnesyl transferase, an enzyme that is involved in the pr...

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

Raymond, Éric E.
Faivre, Sandrine
Alexandre, Jérôme
Goldwasser, François
Besse-Hammer, Tatiana
Awada, Ahmad
Gianella-Borradori, Athos
Jego, V.
Trandafir, Lucia
Rejeb, Narmyn

January 2014

Introduction: MSC1992371A is an aurora kinase inhibitor with potential antitumor activity. Methods: ...

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

Punt, C. J.
van Maanen, L.
Bol, C. J.
Seifert, W. F.
Wagener, D. J.

January 2001

R115777 is a novel selective inhibitor of farnesyl transferase, an enzyme that is involved in the pr...

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling

Kolb, EA
Gorlick, R
Keir, ST
Maris, JM
Lock, RB
Carol, H
Kurmasheva, RT
Reynolds, CP
Kang, MH
Wu, J
Houghton, PJ
Smith, MA

January 2012

RO4929097 is a potent and selective inhibitor of gamma-secretase and as a result is able to inhibit ...

Abstract

Extracted data

PHASE I STUDIES

Abstract

Extracted data

Related items

Related items